10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q1 2016

Filing Information

Form Type	10-Q
Accession Number	`0001140361-16-065775`
Period End Date	20160331
Filing Date	20160516
Fiscal Year	2016
Fiscal Period	Q1
XBRL Instance	ocx-20160331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 58 Income Statement 18 Cash Flow Statement 36 Comprehensive Income 6

Balance Sheet 58 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.86M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$1.78M	USD	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$2.54M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$388.00K	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$262.00K	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$7.90M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$10.93M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$1.17M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$1.23M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	25.39M	shares	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$576.00K	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	25.41M	shares	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$581.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$12.73M	USD	Point-in-time
Common shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	25.39M	shares	Point-in-time
TOTAL ASSETS	`Assets`	$9.65M	USD	Point-in-time
Common shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	25.41M	shares	Point-in-time
Amount due to parent, BioTime	`DueToRelatedPartiesCurrent`	$807.00K	USD	Point-in-time
Amount due to parent, BioTime	`DueToRelatedPartiesCurrent`	$1.32M	USD	Point-in-time
Amount due to affiliates	`DueToRelatedPartiesAndAffiliatesCurrent`	$152.00K	USD	Point-in-time
Amount due to affiliates	`DueToRelatedPartiesAndAffiliatesCurrent`	$40.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$285.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$403.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.75M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.31M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.75M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.31M	USD	Point-in-time
Commitments and contingencies (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 25,412 and 25,391 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	`CommonStockValue`	$35.07M	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 25,412 and 25,391 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	`CommonStockValue`	$34.90M	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.11M	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-350.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-24.13M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-27.06M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.15M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.89M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$9.65M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$12.73M	USD	Point-in-time

Income Statement 18 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$1.12M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.69M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.24M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$250.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$2.93M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.37M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.37M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-2.93M	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$-2.00K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$4.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$4.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-2.00K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-2.93M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-1.37M	USD	1 Quarter
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.08	USD	1 Quarter
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.12	USD	1 Quarter
Weighted average common shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	25.40M	shares	1 Quarter
Weighted average common shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	18.20M	shares	1 Quarter

Cash Flow Statement 36 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.93M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.37M	USD	1 Quarter
Depreciation expense	`Depreciation`	$10.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$11.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$61.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$61.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$216.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$125.00K	USD	1 Quarter
Amount due to parent, BioTime	`IncreaseDecreaseInDueToRelatedParties`	$1.05M	USD	1 Quarter
Amount due to parent, BioTime	`IncreaseDecreaseInDueToRelatedParties`	$511.00K	USD	1 Quarter
Amount due to affiliates	`IncreaseDecreaseInDueToAffiliates`	$31.00K	USD	1 Quarter
Amount due to affiliates	`IncreaseDecreaseInDueToAffiliates`	$113.00K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-31.00K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-126.00K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-185.00K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-192.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-2.17M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-164.00K	USD	1 Quarter
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$11.00K	USD	1 Quarter
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$15.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-15.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-11.00K	USD	1 Quarter
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	-	USD	1 Quarter
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$42.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$42.00K	USD	1 Quarter
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-175.00K	USD	1 Quarter
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.14M	USD	1 Quarter
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$5.86M	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$5.86M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$82.00K	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time

Comprehensive Income 6 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-2.93M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-1.37M	USD	1 Quarter
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-762.00K	USD	1 Quarter
Unrealized (loss) gain on BioTime shares held as available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.09M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-3.69M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-279.00K	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.